Pyridam Farma Tbk PT
IDX:PYFA
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its Industry Average (14.8), the stock would be worth Rp-400.19 (213% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -13.1 | Rp354 |
0%
|
| Industry Average | 14.8 | Rp-400.19 |
-213%
|
| Country Average | 6.3 | Rp-169.34 |
-148%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| ID |
|
Pyridam Farma Tbk PT
IDX:PYFA
|
4T IDR | -13.1 | -8.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
932.9B USD | 57.5 | 45.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
578.6B USD | 24.6 | 21.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
271B CHF | 15.9 | 21 | |
| CH |
|
Novartis AG
SIX:NOVN
|
236.2B CHF | 16.9 | 21.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224.8B GBP | 22.1 | 29.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
287.1B USD | 19.4 | 15.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 834.6 | -74.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 10 | 10.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.8B USD | 17.3 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121B USD | 10.8 | 17.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 3.6 |
| Median | 6.3 |
| 70th Percentile | 14.1 |
| Max | 1 136 900.3 |
Other Multiples
Pyridam Farma Tbk PT
Glance View
PT Pyridam Farma Tbk engages in the production and development of pharmaceutical medicines, and trading of medical supplies. The company is headquartered in Jakarta, Dki Jakarta and currently employs 1,539 full-time employees. The company went IPO on 2001-10-16. The firm operates through two segments: Pharmaceutical Products and Toll Manufacturing Services, and Medical Device Products. Its business consists of production and/or distribution of modern and traditional medicines and distribution of medical devices, such as laboratory equipment and PCR test kits. The company offers products across consumer health, prescription, pyfaesthetic and biomedilab categories. The company produces various kinds of pharmaceuticals products ranging from antibiotics, vitamins and health supplements. The firm offers its products in the form of effervescent tablets, capsules, caplets, syrups and creams. Its prescription production has several properties, such as anti-infection, anti-inflammatory, anti-parkinsonian, anti-epileptic, and other indications. The company provides toll manufacturing services to produce products owned by the Company’s partner companies in accordance with predetermined specifications.
